Nahad Sedaghat

405 total citations
29 papers, 243 citations indexed

About

Nahad Sedaghat is a scholar working on Pathology and Forensic Medicine, Infectious Diseases and Neurology. According to data from OpenAlex, Nahad Sedaghat has authored 29 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pathology and Forensic Medicine, 13 papers in Infectious Diseases and 12 papers in Neurology. Recurrent topics in Nahad Sedaghat's work include Multiple Sclerosis Research Studies (19 papers), SARS-CoV-2 and COVID-19 Research (12 papers) and Long-Term Effects of COVID-19 (7 papers). Nahad Sedaghat is often cited by papers focused on Multiple Sclerosis Research Studies (19 papers), SARS-CoV-2 and COVID-19 Research (12 papers) and Long-Term Effects of COVID-19 (7 papers). Nahad Sedaghat collaborates with scholars based in Iran, United States and Italy. Nahad Sedaghat's co-authors include Hosein Nouri, Masoud Etemadifar, Mehri Salari, Amir Parsa Abhari, Mohammad Reza Maracy, Mehri Salari, Mazdak Ganjalıkhani-Hakemi, Maristella Pitzalis, Maria Laura Idda and Ana Zabalza and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Nahad Sedaghat

27 papers receiving 242 citations

Peers

Nahad Sedaghat

PFM

NEURO

ONCOL

SURGE

Amir Parsa Abhari Iran

Rohini Samudralwar United States

Lucio Cosco Italy

Artemis Papadaki United Kingdom

Stefania Calvisi Italy

Simon A. Balogun Nigeria

Lucia Fidanza Italy

Domenica Zaino Italy

Quan Cao China

Seyyedmohammadsadeq Mirmoeeni Iran

Amir Parsa Abhari Iran

Nahad Sedaghat

85 ×0.6

PFM

76 ×0.6

NEURO

19 ×0.7

ONCOL

10 ×0.5

SURGE

Citations per year, relative to Nahad Sedaghat Nahad Sedaghat (= 1×) peers Amir Parsa Abhari

Countries citing papers authored by Nahad Sedaghat

Since Specialization

Citations

This map shows the geographic impact of Nahad Sedaghat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nahad Sedaghat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nahad Sedaghat more than expected).

Fields of papers citing papers by Nahad Sedaghat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nahad Sedaghat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nahad Sedaghat. The network helps show where Nahad Sedaghat may publish in the future.

Co-authorship network of co-authors of Nahad Sedaghat

This figure shows the co-authorship network connecting the top 25 collaborators of Nahad Sedaghat. A scholar is included among the top collaborators of Nahad Sedaghat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nahad Sedaghat. Nahad Sedaghat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Etemadifar, Masoud, et al.. (2025). Dimethyl Fumarate for Pediatric-Onset Multiple Sclerosis: A Systematic Review. Pediatric Neurology. 167. 52–59. 1 indexed citations

Salari, Mehri, et al.. (2025). Gynecologic health of women with multiple sclerosis: An overview on the current status and findings of Pap tests in a low-income setting. PLoS ONE. 20(3). e0320069–e0320069.

Salari, Mehri, et al.. (2024). Distal median nerve dysfunction and carpal tunnel syndrome in people with multiple sclerosis treated with teriflunomide: an electrodiagnostic study. Neurological Sciences. 46(2). 855–860. 1 indexed citations

Sedaghat, Nahad, et al.. (2024). Anxiolytic Effect of Jasmine Aromatherapy in Pediatric Dental Procedures: A Single-Blinded Randomized Placebo-Controlled Trial. Frontiers in Dentistry. 21. 39–39.

Nouri, Hosein, et al.. (2024). Anti-CD20 therapies for pediatric-onset multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders. 91. 105849–105849. 2 indexed citations

Abbasi, Saeed, et al.. (2023). Effect of enteral probiotics on prognostic scores and C-reactive protein levels in critically ill multiple trauma patients: A randomized, double-blind, placebo-controlled clinical trial. Clinical Nutrition ESPEN. 55. 30–37. 3 indexed citations

Minakari, Mohammad & Nahad Sedaghat. (2022). Endoscopic clipping of a complicated esophageal perforation following pneumatic dilation for achalasia: A case study and literature review. SHILAP Revista de lepidopterología. 10(11). e6620–e6620. 1 indexed citations

Sedaghat, Nahad, et al.. (2022). Multiple sclerosis in sarcoidosis patients: Two case reports. SHILAP Revista de lepidopterología. 10(9). e6332–e6332. 1 indexed citations

Etemadifar, Masoud, Amir Parsa Abhari, Hosein Nouri, et al.. (2022). Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis. Human Vaccines & Immunotherapeutics. 18(1). 2041945–2041945. 10 indexed citations

10.

Nouri, Hosein, Maristella Pitzalis, Maria Laura Idda, et al.. (2022). Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: A practical review and meta-analysis. medRxiv. 5 indexed citations

11.

Etemadifar, Masoud, Hosein Nouri, Mehri Salari, & Nahad Sedaghat. (2022). Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse. Human Vaccines & Immunotherapeutics. 18(1). 2033540–2033540. 9 indexed citations

12.

Madani, Mahboobeh, et al.. (2022). Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model. PLoS ONE. 17(12). e0278488–e0278488. 3 indexed citations

13.

Etemadifar, Masoud, et al.. (2022). Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine. Journal of the Neurological Sciences. 444. 120518–120518. 4 indexed citations

14.

Etemadifar, Masoud, Hosein Nouri, Maristella Pitzalis, et al.. (2022). Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis. Journal of Neurology Neurosurgery & Psychiatry. 93(9). 986–994. 26 indexed citations

15.

Etemadifar, Masoud, et al.. (2022). Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors. Multiple Sclerosis and Related Disorders. 58. 103488–103488. 4 indexed citations

16.

Sedaghat, Nahad, et al.. (2021). Re-Evaluating the Effect of Preoperative Tranexamic Acid on Blood Loss and Field Quality During Rhinoplasty: A Randomized Double-Blinded Controlled Trial. Aesthetic Plastic Surgery. 46(3). 1314–1320. 13 indexed citations

17.

Etemadifar, Masoud, Nahad Sedaghat, Mohammad Reza Maracy, et al.. (2021). COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?. Multiple Sclerosis and Related Disorders. 51. 102915–102915. 42 indexed citations

18.

Etemadifar, Masoud, Hosein Nouri, Mohammad Reza Maracy, et al.. (2021). Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis. Revue Neurologique. 178(1-2). 121–128. 22 indexed citations

19.

Etemadifar, Masoud, et al.. (2021). Myasthenia gravis and coronavirus disease 2019: A report from Iran. PubMed. 20(3). 162–165. 2 indexed citations

20.

Etemadifar, Masoud, et al.. (2021). Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies. Journal of Research in Medical Sciences. 26(1). 85–85. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact